https://bio.nikkeibp.co.jp/atcl/news/p1/24/03/29/11757/
The company’s basic technology involves introducing an animal reprogramming factor into cells using a plasmid vector and culturing it under specific conditions to create iPS cells. The company is currently developing regenerative medicine products using canine iPS cells. As a candidate for the next pipeline, it also succeeded in producing cat iPS cells. In the future, they hope to produce horse iPS cells as well.
As a first product, mesenchymal stem cells (MSCs) differentiated from canine allogeneic iPS cells will be produced as cell medicines for systemic inflammatory diseases, followed by veterinary medicine for platelets, blood cells, cardiomyocytes, pancreatic islet beta cells, and nephron progenitor cells.
Vetanic Co. develops regenerative medicine products using dog and cat iPS cell production technology